Actively Recruiting
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Led by Zeenat Qureshi Stroke Institute · Updated on 2026-04-24
1000
Participants Needed
13
Research Sites
217 weeks
Total Duration
On this page
Sponsors
Z
Zeenat Qureshi Stroke Institute
Lead Sponsor
C
Chiesi USA, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim is to compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen.
CONDITIONS
Official Title
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older and less than 100 years
- New neurological deficits started within 12 hours before enrollment
- Clinical signs of stroke affecting language, movement, cognition, gaze, vision, or neglect
- National Institutes of Health Stroke Scale score of 1 or higher
- Glasgow Coma Scale score of 5 or higher at enrollment
- Brain CT scan showing intraparenchymal hematoma with volume over 5 cc
- Systolic blood pressure between 150 and less than 220 mmHg on two measurements 5 to 10 minutes apart
- Signed informed consent before hospital discharge and agreement to 90- and 180-day follow-ups
- Patients with anticoagulant-related ICH if anticoagulant reversal is done per guidelines
- Patients undergoing surgical evacuation unless surgery occurs within 6 hours of treatment start
- Patients needing external ventricular drainage as per guidelines
You will not qualify if you...
- Unreliable time of symptom onset
- Known brain tumors, arteriovenous malformations, or aneurysms
- Intracerebral hematoma caused by trauma
- ICH located in infratentorial regions like pons or midbrain (cerebellar ICH allowed)
- Candidates for immediate neurosurgical intervention
- Pregnancy, recent childbirth within 30 days, or active breastfeeding
- History of bleeding disorders except anticoagulant-related ICH
- Platelet count below 50,000/mm3
- Known allergy to nicardipine or clevidipine
- Living will that limits aggressive ICU care
- Allergies to soybeans, soy products, eggs, or egg products
- Disorders of lipid metabolism such as hyperlipemia, lipoid nephrosis, or acute pancreatitis with hyperlipidemia
- Severe aortic stenosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
University of California
Irvine, California, United States, 92696-7600
Actively Recruiting
2
Antelope Valley Medical Center
Lancaster, California, United States, 93534
Actively Recruiting
3
Stanford Medical Center (Stanford Health Care)
Palo Alto, California, United States, 94304
Actively Recruiting
4
Cleveland Clinic Martin North Hospital
Stuart, Florida, United States, 34994
Actively Recruiting
5
University of South Florida
Tampa, Florida, United States, 33606
Actively Recruiting
6
Augusta University-Neuroscience Center
Augusta, Georgia, United States, 30912
Actively Recruiting
7
University of Michigan Health-West
Wyoming, Michigan, United States, 49519
Actively Recruiting
8
University of Missouri
Columbia, Missouri, United States, 65212
Actively Recruiting
9
Albany Medical Center
Albany, New York, United States, 12208
Actively Recruiting
10
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Actively Recruiting
11
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Actively Recruiting
12
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Actively Recruiting
13
University of Texas Health Science Center San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here